PARSIPPANY, N.J. / Feb 20, 2025 / Business Wire / Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the following investor conferences.
Investors and other interested parties can access live audio webcasts of the presentations by visiting http://investor.zoetis.com/events-presentations. Replays will also be available on the Zoetis website at the conclusion of each event.
About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.
| Last Trade: | US$158.67 |
| Daily Change: | 1.62 1.03 |
| Daily Volume: | 1,165,377 |
| Market Cap: | US$70.640B |
May 06, 2025 February 14, 2025 February 13, 2025 February 04, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
